中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

27 records (took 0.018 seconds)

    ZWITTERIONIC ZINC(II) CARBOXYLATE COMPOUNDS AND THEIR USE
    11.
    发明申请
    ZWITTERIONIC ZINC(II) CARBOXYLATE COMPOUNDS AND THEIR USE 有权

    公开(公告)号：US20180057512A1

    公开(公告)日：2018-03-01

    申请号：US15251300

    申请日：2016-08-30

    Applicant: Southern Medical University ,  Macau University of Science and Technology

    Inventor： Jin-Xiang Chen ,  Bin Sun ,  Hai-Qing Zhao ,  Bao-Ping Xie ,  Li-Ping Bai ,  Zhi-Hong Jiang

    IPC: C07F3/06 ,  C12Q1/70

    CPC classification number: C07F3/06 ,  C12Q1/703

    Abstract: A method of preparing a crystalline zwitterionic zinc(II)-carboxylate compound includes the steps of preparing a mixture of zinc(II) ions and a first pyridyl ligand having three carboxylic acid moieties; subjecting the mixture to conditions under which a precipitate is formed; separating the precipitate; adding a solvent and optionally a second pyridyl ligand to the separated precipitate; subjecting the obtained mixture to conditions under which crystals of the zwitterionic zinc(II)-carboxylate compound are formed; and separating the crystals of the zwitterionic zinc(II)-carboxylate compound. Preferably but not exclusively, the crystalline zwitterionic zinc(II)-carboxylate compound essentially consists of at least one 1D coordination polymer. The compounds are suitable for providing a sensing platform for detecting the presence or amount of target nucleic acid, particularly HIV-1 ds-DNA, with specificity, and, thus, a method of detecting a target nucleic acid sequence in a sample and a kit including the compounds and an oligonucleotide probe are also provided.

    Method and pharmaceutical composition for treating cancer
    13.
    发明授权
    Method and pharmaceutical composition for treating cancer 有权

    公开(公告)号：US11149271B2

    公开(公告)日：2021-10-19

    申请号：US16120606

    申请日：2018-09-04

    Applicant: Macau University of Science and Technology

    Inventor： Zhi-Hong Jiang ,  Tong-Meng Yan ,  Kai-Yue Cao

    IPC: C12N15/113 ,  A61P35/00

    Abstract: A method of treating a subject suffering from cancer includes administering an effective amount of a RNA molecule to the subject, wherein the RNA molecule is isolated or derived from a plant of the genus Taxus. A method of inhibiting growth or proliferation of cancer cells includes contacting cancer cells with the RNA molecule; and a pharmaceutical composition for treating cancer includes the RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector include the double-stranded RNA molecule.

    Crystalline contrast agent for magnetic resonance imaging, kit and composition comprising it and their use
    14.
    发明授权
    Crystalline contrast agent for magnetic resonance imaging, kit and composition comprising it and their use 有权

    公开(公告)号：US10759757B2

    公开(公告)日：2020-09-01

    申请号：US15271368

    申请日：2016-09-21

    Applicant: Southern Medical University ,  Macau University of Science and Technology

    Inventor： Jinxiang Chen ,  Jianxin Pang ,  Shuwen Liu ,  Li-Ping Bai ,  Zhi-Hong Jiang

    IPC: C07D213/80 ,  A61K49/10 ,  A61K49/18

    Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.

    METHOD OF ISOLATING PHENANTHROINDOLIZIDINE ALKALOIDS FROM TYLOPHORA ATROFOLLICULATA, COMPOSITIONS COMPRISING THEM AND THEIR MEDICAL USE
    17.
    发明申请
    METHOD OF ISOLATING PHENANTHROINDOLIZIDINE ALKALOIDS FROM TYLOPHORA ATROFOLLICULATA, COMPOSITIONS COMPRISING THEM AND THEIR MEDICAL USE 审中-公开

    公开(公告)号：US20170312267A1

    公开(公告)日：2017-11-02

    申请号：US15142407

    申请日：2016-04-29

    Applicant: Macau University of Science and Technology

    Inventor： Zhi-Hong Jiang ,  Jing-Rong Wang ,  Cheng-Yu Chen ,  Guo-Yuan Zhu

    IPC: A61K31/4745 ,  A61K36/24

    CPC classification number: A61K31/4745 ,  A61K36/27

    Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.

    Nucleic acid molecules and uses thereof
    18.
    发明授权
    Nucleic acid molecules and uses thereof 有权

    公开(公告)号：US11866704B2

    公开(公告)日：2024-01-09

    申请号：US17247265

    申请日：2020-12-06

    Applicant: Macau University of Science and Technology

    Inventor： Zhi-Hong Jiang ,  Kai-Yue Cao ,  Yu Pan ,  Tong-Meng Yan

    IPC: C12N15/113

    CPC classification number: C12N15/113 ,  C12N2310/14 ,  C12N2310/32

    Abstract: A method of treating a subject suffering from cancer comprising a step of administering an effective amount of a group of double-stranded RNA molecules to the subject, wherein the RNA molecule is isolated or derived from a bacteria of the genus Escherichia. A method of inhibiting growth or proliferation of cancer cells comprising a step of contacting said cells with said RNA molecule; and a pharmaceutical composition for treating cancer comprising said RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector comprising the double-stranded RNA molecule.

    Method of isolating sphingolipids from cordyceps and their use
    20.
    发明授权
    Method of isolating sphingolipids from cordyceps and their use 有权

    公开(公告)号：US11357806B2

    公开(公告)日：2022-06-14

    申请号：US15131218

    申请日：2016-04-18

    Applicant: Macau University of Science and Technology

    Inventor： Zhi-Hong Jiang ,  Jing-Rong Wang ,  Jia-Ning Mi ,  Junping Kou ,  Yuwei Han ,  Yingqiong Xu

    IPC: A61K36/068 ,  A61K31/133 ,  A61K31/164 ,  A61K31/688 ,  G01N30/34 ,  G01N30/72 ,  B01D15/42 ,  C12Q1/04 ,  G01N33/92 ,  G01N30/00 ,  G01N30/02

    Abstract: A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from Cordyceps, in particular from wild-type Cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from Cordyceps, in particular from wild-type Cordyceps. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject. Still further in accordance with the present invention is a composition, in particular a pharmaceutical composition comprising at least one sphingolipid portion.

Patent Agency Ranking